Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Human adipose stem cell conditioned medium has a pro-fibrotic and EMT-stimulating effect on urethral fibroblasts in vitro.

Barasa P., Baltrukonyte E., Simoliune I., Grybas A., Baltriukiene D.

Laboratory Study on Scar, Chronic Inflammation, published in Eur J Cell Biol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Eur J Cell Biol (2026)
Country
Germany
Reported sample size
—
Source database
PubMed
PMID
41996833
DOI
10.1016/j.ejcb.2026.151538

Abstract (original English)

Fibrosis, characterized by excessive deposition of scar tissue, leads to the dysfunction of various organs. An urethral stricture, or pathological narrowing of the urethra, is an example of such scarring. The use of human adipose stem cell conditioned medium (HASC-CM) has shown promise as an anti-fibrotic treatment in vivo, as molecules produced by HASCs exhibit anti-inflammatory and fibrosis-modulating properties. However, HASC-CM has also been demonstrated to activate epithelial-to-mesenchymal transition (EMT) in cancer-associated cells. To elucidate whether HASC-CM promotes EMT or myofibroblast activation, we investigated its effects on primary human urethral fibroblasts (HUFs) and prostatic fibroblasts of the WPMY-1 line. We showed that HASC-CM promotes migration speed in HUFs but not in WPMY-1 cells while also increasing vimentin levels in the cells, both markers of EMT. Moreover, HASC-CM suppressed SMAD5 signalling in HUFs without altering SMAD3 signalling in either cell type. In addition, HASC-CM treatment induced myocardin-related transcription factor A (MRTF-A) nuclear translocation and increased amount of alpha smooth muscle actin (αSMA) in HUFs, indicating a shift towards the myofibroblast phenotype. We conclude that the effect of HASC-CM on WPMY-1 cells is negligible, however, this type of treatment has a pro-fibrotic and EMT-stimulating effect on HUFs.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansCulture Media, ConditionedEpithelial-Mesenchymal TransitionFibroblastsFibrosisUrethraAdipose TissueStem CellsCells, CulturedMyofibroblasts

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research